1. Roukos DH. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic? Expert Rev Proteomics. 2012 Aug;9(4):349-53. doi: 10.1586/epr.12.37.

2. Ku CS, Polychronakos C, Tan EK, Naidoo N, Pawitan Y, Roukos DH, Mort M, Cooper DN. A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease. Mol Psychiatry. 2012 May 29. doi: 10.1038/mp.2012.58.

3. Ku CS, Roukos DH. From next-generation sequencing to nanopore technologies: paving the way for personalized health. Experts Rev Med Dev 2013 Jan. 10.1586/ERD.12.53

4. Ku CS, Roukos DH. De novo mutations, protein-protein interactions and functional regulatory networks toward novel diagnostics in autism. Expert Rev Proteomics. 2012 Oct;9(5):473-6. doi: 10.1586/epr.12.43.

5. Roukos DH. Integrative deep-sequencing analysis of cancer samples: Discoveries and clinical challenges. Pharmacogenomics J., 2013 (in press).

6. Zografos G, Liakakos T, Roukos DH. Integrated clinical genomics: new horizon for diagnostics and biomarkers discoveries in cancer. Expert Rev Mol Diagn 2013; 13 (1), doi: 10.1586/erm.12. 132 .

7. Roukos DH, Papaloukas C, Tzaphlidou M. From targeted monotherapy to combined braf-mek inhibitors and integrated genome analysis for m elanoma treatment. Future Oncol. 2013 Jan; 9(1): 1-4. doi: 10.2217/FON.12.169.

8. Roukos DH, Ziogas DE, Papaloukas C, Baltogiannis G. Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. Future Oncol. 2012 Nov;8(11):1373-6. doi: 10.2217/fon.12.140.

9. Roukos DH. Dynamics of genome 'iPOP': predicting disease or 'narciss-ome'? Expert Rev Mol Diagn. 2012 Jul;12(6):545-8.

10. Roukos DH, Ku CS. Clinical cancer genome and precision medicine. Ann Surg Oncol. 2012 Nov; 19(12):3646-50. doi: 10.1245/s10434-012-2542-9.

1. Ku CS, Cooper DN, E Ziogas D, Halkia E, Tzaphlidou M, Roukos DH. Research and clinical applications of cancer genome sequencing. Curr Opin Obstet Gynecol. 2012 Nov 20. [Epub ahead of print] PubMed PMID: 23108289.

2. Ziogas DE, Baltogiannis G, Spiliotis J, Tzaphlidou M, Roukos DH. Genome-based diagnostics and predictive tools: a new epoch for breast cancer management. Future Oncol. 2012 Oct;8(10):1211-4. doi: 10.2217/fon.12.115. PubMed PMID: 23130921.

3. Roukos D, Batsis C, Baltogiannis G. Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. Expert Rev Anticancer Ther. 2012 Oct;12(10):1245-8. doi: 10.1586/era.12.105. PubMed PMID: 23176613.

4. Katsios C, Papaloukas C, Tzaphlidou M, Roukos DH. Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications? Expert Rev Mol Diagn. 2012 Sep;12(7):667-70. doi: 10.1586/erm.12.68. PubMed PMID: 23153232.

5. Ku C, Cooper D, Iacopetta B, Roukos D. Integrating next-generation sequencing into the diagnostic testing of inherited cancer predisposition. Clin Genet. 2012 Sep 28. doi: 10.1111/cge.12028. [Epub ahead of print] PubMed PMID: 23020236.

6. Ziogas DE, Katsios CS, Tzaphlidou M, Roukos DH. Targeted therapy: overcoming drug resistance with clinical cancer genome. Expert Rev Anticancer Ther. 2012 Jul;12(7):861-4. doi: 10.1586/era.12.68. PubMed PMID: 22845399.

7. Cho W, Ziogas DE, Katsios C, Roukos DH. Emerging personalized oncology: sequencing and systems strategies. Future Oncol. 2012 Jun;8(6):637-41. doi: 10.2217/fon.12.44. PubMed PMID: 22764759.

8. Ku CS, Cooper DN, Roukos DH. The 'sequence everything' approach and personalized clinical decision challenges. Expert Rev Mol Diagn. 2012 May;12(4):319-22. doi: 10.1586/erm.12.20. Review. PubMed PMID: 22616695.

9. Roukos DH. Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn. 2012 Apr;12(3):215-8. doi: 10.1586/erm.12.7. PubMed PMID: 22468809.

10. Roukos DH. Differential signaling transduction networks for clinical robustness. Expert Rev Proteomics. 2012 Apr;9(2):111-4. doi: 10.1586/epr.12.14. PubMed PMID: 22462780.

11. Roukos DH. Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics. 2012 Apr;4(2):119-23. doi: 10.2217/epi.12.1. PubMed PMID: 22449182.

12. Roukos DH. Biotechnological, genomics and systems-synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices. 2012 Mar;9(2):97-101. doi: 10.1586/erd.11.68. Review. PubMed PMID: 22404769.

13. Roukos DH. Novel cancer drugs based on epigenetics, miRNAs and their interactions. Epigenomics. 2011 Dec;3(6):675-8. doi: 10.2217/epi.11.91. PubMed PMID: 22126285.

14. Roukos DH. Cancer genome sequencing and functional genomics: from translational to clinical medicine. Pharmacogenomics. 2011 Oct;12(10):1371-4. doi: 10.2217/pgs.11.108. PubMed PMID: 22008044.

15. Ziogas DE, Roukos DH. Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Rev Mol Diagn. 2011 Sep;11(7):663-6. doi: 10.1586/erm.11.56. PubMed PMID: 21902524.

16. Roukos DH. Chromatin: a key player in complex gene regulation and future cancer therapeutics. Epigenomics. 2011 Aug;3(4):395-9. doi: 10.2217/epi.11.70. PubMed PMID: 22126199.

17. Katsios CS, Ziogas DE, Roukos DH. Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. Pharmacogenomics. 2011 Aug;12(8):1081-5. doi: 10.2217/pgs.11.58. PubMed PMID: 21843060.

18. Roukos DH. Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices. 2011 Jul;8(4):409-13. doi: 10.1586/erd.11.35. Review. PubMed PMID: 21728725.

19. Roukos DH. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics. 2011 May;12(5):695-8. doi: 10.2217/pgs.11.28. PubMed PMID: 21619431.

20. Katsios C, Roukos DH. Missing heritability, next-generation genome-wide association studies and primary cancer prevention: an Atlantean illusion? Future Oncol. 2011 Apr;7(4):477-80. doi: 10.2217/fon.11.29. PubMed PMID: 21463134.

21. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 2011 Apr;11(2):81-92. doi: 10.1038/tpj.2010.81. Epub 2010 Oct 26. Review. PubMed PMID: 20975737.

22. Roukos DH. 'Big' science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn. 2011 Mar;11(2):123-6. doi: 10.1586/erm.11.4. PubMed PMID: 21405960.

23. Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices. 2011 Mar;8(2):123-6. doi: 10.1586/erd.11.5. PubMed PMID: 21381902.

24. Ziogas DE, Katsios C, Roukos DH. From traditional molecular biology to network oncology. Future Oncol. 2011 Feb;7(2):155-9. doi: 10.2217/fon.10.190. PubMed PMID: 21345133.

25. Katsios C, Ziogas DE, Roukos DH. New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology. Expert Rev Anticancer Ther. 2011 Jan;11(1):5-8. doi: 10.1586/era.10.176. Review. PubMed PMID: 21166504.

26. Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices. 2010 Nov;7(6):723-6. doi: 10.1586/erd.10.68. PubMed PMID: 21050081.

27. Katsios C, Zoras O, Roukos DH. Cancer genome sequencing and potential application in oncology. Future Oncol. 2010 Oct;6(10):1527-31. doi: 10.2217/fon.10.115. Review. PubMed PMID: 21062151.

28. Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics. 2010 Mar;11(3):283-7. doi: 10.2217/pgs.10.36. Review. PubMed PMID: 20235782.

29. Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther. 2010 Feb;10(2):123-8. doi: 10.1586/era.09.177. PubMed PMID: 20131987.

30. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn. 2010 Jan;10(1):33-48. doi: 10.1586/erm.09.69. Review. PubMed PMID: 20014921.